Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immuron Ltd.

www.immuron.com

Latest From Immuron Ltd.

Common Treatment May Be Removed In Alcoholic Hepatitis Trials

Given effect corticosteroids have on patients, US FDA asks whether they can be excluded from use in alcoholic hepatitis clinical trials.
Gastrointestinal Drug Approval Standards

Pipeline Watch: Phase III Starts With NSR-REP1 Gene Therapy, ALLN-177 And BIVV009

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

IPOs In Review: Biopharma Offerings Bounced Back In 2017 As Returns Rose

With an average return of 33.2% in 2017, the number of biopharma IPOs that launched last year rose to 42 after falling to 30 in 2016 compared with 62 in 2015. Following a rough fourth quarter for biopharma stocks, will the IPO momentum continue in 2018?

Financing Business Strategies

IPO Update: New Offerings Outperform As September Ends With Biopharma Trifecta

There have been 29 IPOs in the US through the third quarter of 2017 with an average return of 35.2%, including three offerings on the same day – Deciphera, Nightstar and NuCana – near the end of September.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
    • Large Molecule
      • Antibodies
    • Transgenics
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Immune Disorders
  • Infectious & Viral Diseases
  • Alias(es)
  • Anadis Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Australia
  • Parent & Subsidiaries
  • Immuron Ltd.
  • Senior Management
  • Thomas Liquard, CEO
    Peter Vaughan, CFO
    Jerry Kanellos, COO & CSO
    Travis Robins, Dir, US Sales
  • Contact Info
  • Immuron Ltd.
    Phone: (61) 3 9824 5254
    Chapman St., Ste. 10- 25
    Blackburn North, 3130
    Australia
Advertisement
Advertisement
UsernamePublicRestriction

Register